NFL BIOSCIENCES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.892 EUR | +3.96% |
|
-9.26% | +31.39% |
| Apr. 12 | Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... |  |
| Apr. 12 | NFL Biosciences: successful capital increase | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents.
At the end of 2022, the company has one product in phase II/III clinical development (NFL-101) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol reduction).
Calendar
2024-09-29
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.82
EUR
Average target price
4.2
EUR
Spread / Average Target
+130.77%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.39% | 15.75M | |
| -2.54% | 103B | |
| +1.94% | 95.28B | |
| +1.46% | 22.15B | |
| -15.64% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -12.85% | 16.05B | |
| +5.68% | 13.68B | |
| +34.70% | 12.17B |
- Stock Market
- Equities
- ALNFL Stock
- News NFL Biosciences
- NFL Biosciences Raises EUR3 Million for Clinical Trial, Partnerships
